Accuray reported a solid third fiscal quarter with a 27% year-over-year increase in gross orders, reaching $106 million. Net revenue was $99.5 million and net income was $2.6 million, or $0.03 per share. The company ended the quarter with $91.6 million in cash, cash equivalents, and short-term restricted cash.
Gross orders increased 27% year-over-year to $106.0 million, including 11 orders from China.
Net orders of $76.7 million, an increase of 28% year-over-year.
Total backlog increased 15% year-over-year to $569.9 million.
Net revenue of $99.5 million, net income of $2.6 million, Adjusted EBITDA of $11.3 million
Given the continued evolution of the COVID-19 pandemic and the uncertainty surrounding its impact on the global economy and the healthcare industry, Accuray believes it is prudent to withdraw its previous full fiscal year 2020 financial guidance regarding revenue and adjusted EBITDA.
Visualization of income flow from segment revenue to net income